| Literature DB >> 35888695 |
Hanan A Alfawaz1, Afaf El-Ansary2, Laila Al-Ayadhi3, Ramesa Shafi Bhat4, Wail M Hassan5.
Abstract
Autism spectrum disorders (ASDs) are neurodevelopmental disorders that clinically presented as impaired social interaction, repetitive behaviors, and weakened communication. The use of bee pollen as a supplement rich in amino acids amino acids, vitamins, lipids, and countless bioactive substances may lead to the relief of oxidative stress, neuroinflammation, glutamate excitotoxicity, and impaired neurochemistry as etiological mechanisms autism. Thirty young male Western albino rats were randomly divided as: Group I-control; Group II, in which autism was induced by the oral administration of 250 mg propionic acid/kg body weight/day for three days followed by orally administered saline until the end of experiment and Group III, the bee pollen-treated group, in which the rats were treated with 250 mg/kg body weight of bee pollen for four weeks before autism was induced as described for Group II. Markers related to oxidative stress, apoptosis, inflammation, glutamate excitotoxicity, and neurochemistry were measured in the brain tissue. Our results indicated that while glutathione serotonin, dopamine, gamma-aminobutyric acid (GABA), GABA/Glutamate ratio, and vitamin C were significantly reduced in propionic acid-treated group (p < 0.05), glutamate, IFN-γ, IL-1A, IL-6, caspase-3, and lipid peroxide levels were significantly elevated (p < 0.05). Bee pollen supplementation demonstrates protective potency presented as amelioration of most of the measured variables with significance range between (p < 0.05)-(p < 0.001).Entities:
Keywords: apoptosis; autism spectrum disorders; cytokines; gut microbiota; neurotransmitters; oxidative stress; propionic acid
Year: 2022 PMID: 35888695 PMCID: PMC9323335 DOI: 10.3390/metabo12070571
Source DB: PubMed Journal: Metabolites ISSN: 2218-1989
Mean ± S.D. of the measured variables in PPA-treated (Group II) and bee pollen-protected animals (Group III) compared to controls. GABA: gamma-aminobutyric acid, IFN-γ: interferon gamma, IL-x: interleukin x, VEGF: vascular endothelial growth factor, TNF-α: tumor necrosis factor alpha. * denotes significance between ASD model or BP-protected ASD model and control; # denotes significance between BP-protected ASD model and ASD model; $ denotes significance between the three studied groups.
| Variables | Control | ASD Model | Bee Pollen-Protected ASD Model |
|---|---|---|---|
| Norepinephrine (ng/100 mg) | 4.92 ± 0.618 | 3.25 ± 0.36 *,# | 3.79 ± 0.15 *,# |
| Serotonin (ng/100 mg) | 6.20 ± 0.78 | 3.78 ± 0.56 *,# | 4.36 ± 0.42 *,# |
| Dopamine (ng/100 mg) | 21.12 ± 2.72 | 13.69 ± 0.80 *,# | 16.09 ± 0.71 *,# |
| GABA (ng/100 mg) | 2.95 ± 0.24 | 1.40 ± 0.29 *,# | 1.70 ± 0.24 *,# |
| Glutamate (µg/mg) | 1.44 ± 0.11 | 3.05 ± 0.27 *,# | 1.85 ± 0.10 *,# |
| GABA/Glutamine | 2.04 ± 0.06 | 0.46 ± 0.11 *,# | 0.92 ± 0.12 *,# |
| Glutamine (µg/mg) | 0.70 ± 0.07 | 0.64 ± 0.08 *,# | 0.71 ± 0.05 *,# |
| Glutamate/Glutamine | 2.09 ± 0.19 | 4.80 ± 0.52 *,# | 2.62 ± 0.30 *,# |
| IFN-γ (pg/mL) | 120.71 ± 167.85 | 127.09 ± 192.57 $ | 21.86 ± 32.80 $ |
| IL-1A (pg/mL) | 190.54 ± 68.50 | 217.85 ± 76.89 *,# | 125.94 ± 37.27 *,# |
| IL-6 (pg/mL) | 18.87 ± 4.69 | 46.44 ± 61.93 $ | 25.64 ± 27.15 $ |
| IL-10 (pg/mL) | 213.86 ± 212.98 | 76.76 ± 36.44 $ | 94.08 ± 28.87 $ |
| IL-12 (pg/mL) | 82.07 ± 8.65 | 71.03 ± 7.57 $ | 70.11 ± 13.10 $ |
| VEGF (pg/mL) | 5.95 ± 2.43 | 5.36 ± 2.64 $,# | 3.58 ± 0.85 *,# |
| TNF-α (pg/mL) | 17.11 ± 1.39 | 14.50 ± 0.91 $,# | 13.95 ± 3.27 *,# |
| Caspase-3 (u/100 mg) | 112.66 ± 4.20 | 134.79 ± 3.27 *,# | 124.23 ± 2.89 *,# |
| Glutathione (µg/mL) | 36.44 ± 2.43 | 35.07 ± 2.83 *,$ | 43.65 ± 2.09 *,# |
| Vitamin C (µg/mL) | 20.16 ± 2.00 | 11.74 ± 1.16 *,# | 20.42 ± 3.42 $,# |
| Lipid peroxides | 0.35 ± 0.01 | 0.39 ± 0.01 *,# | 0.36 ± 0.01 $,# |
Figure 1Levels of the biomarkers used in ASD (Group II; APP-treated), ASD/bee pollen-protected (Group III), and control (group I) rats. * denotes a statistically significant difference between groups I and II, # denotes a statistically significant difference between groups I and III, and $ denotes statistically significant difference between groups II and III. NE: norepinephrine, 5-HT: serotonin, DA: dopamine, GABA: gamma-aminobutyric acid, Glut: glutamate, Gln: glutamine, IFN-γ: interferon gamma, IL-x: interleukin x, VEGF: vascular endothelial growth factor, TNF-α: tumor necrosis factor alpha, Casp-3: caspase 3, GSH: glutathione, VitC: vitamin C, LipPerox: lipid peroxidase.
Spearman correlation matrix. Only significant correlations are shown (p value < 0.05). Correlation heatmap depicts perfect positive (darks blue) and negative (dark red) correlations and no correlation (white). Significance heatmap depicts p values ranging from 0.000 (green) to 0.05 (orange). NE: norepinephrine, 5-HT: serotonin, DA: dopamine, GABA: gamma-aminobutyric acid, Glut: glutamate, Gln: glutamine, IL-12: interleukin 12, VEGF: vascular endothelial growth factor, TNF-α: tumor necrosis factor alpha, GSH: glutathione, VitC: vitamin C, MDA: 3,4-methylenedioxyamphetamine.
| Variable | Correlated Variables | Spearman Correlation (R) | Variable | Correlated Variables | Spearman Correlation (R) | ||
|---|---|---|---|---|---|---|---|
|
| NE | −0.829 | 0.000 |
| 5-HT | 0.82 | 0.000 |
| 5-HT | −0.69 | 0.002 | DA | 0.888 | 0.000 | ||
| DA | −0.818 | 0.000 | Caspase 3 | −0.865 | 0.000 | ||
| Caspase 3 | 0.771 | 0.000 | GABA | 0.919 | 0.000 | ||
| GABA | −0.686 | 0.002 | Glut | −0.91 | 0.000 | ||
| Glut | 0.756 | 0.000 | GABA/Glut | 0.95 | 0.000 | ||
| GABA/Glut | −0.748 | 0.000 | Glut/Gln | −0.85 | 0.000 | ||
| Glut/Gln | 0.735 | 0.001 | IL-12 | 0.473 | 0.047 | ||
| VEGF | 0.652 | 0.006 | TNF-α | 0.557 | 0.016 | ||
| TNF-α | 0.649 | 0.007 | VitC | 0.634 | 0.005 | ||
| VitC | −0.646 | 0.004 | MDA | −0.702 | 0.001 | ||
| MDA | 0.717 | 0.001 | |||||
|
| GABA | −0.846 | 0.000 |
| Caspase 3 | −0.913 | 0.000 |
| Glut | 0.856 | 0.000 | GABA | 0.839 | 0.000 | ||
| GABA/Glut | −0.874 | 0.000 | Glut | −0.851 | 0.000 | ||
| Glut/Gln | 0.872 | 0.000 | GABA/Glut | 0.89 | 0.000 | ||
| IL-12 | −0.527 | 0.024 | Glut/Gln | −0.86 | 0.000 | ||
| TNF-α | −0.499 | 0.035 | TNF-α | 0.508 | 0.031 | ||
| VitC | −0.633 | 0.005 | VitC | 0.596 | 0.009 | ||
| MDA | 0.71 | 0.001 | MDA | −0.778 | 0.000 | ||
|
| DA | 0.827 | 0.000 |
| Glut | −0.781 | 0.000 |
| Caspase 3 | −0.839 | 0.000 | GABA/Glut | 0.926 | 0.000 | ||
| GABA | 0.859 | 0.000 | Glut/Gln | −0.778 | 0.000 | ||
| GABA/Glut | 0.853 | 0.000 | VitC | 0.521 | 0.027 | ||
| Glut/Gln | −0.824 | 0.000 | MDA | −0.605 | 0.008 | ||
| TNF-α | 0.547 | 0.019 |
| GSH | −0.75 | 0.001 | |
| VitC | −0.658 | 0.003 | MDA | 0.528 | 0.035 | ||
|
| Glut/Gln | −0.862 | 0.000 | TNF-α | 0.746 | 0.000 | |
| TNF-α | 0.486 | 0.041 |
| VitC | 0.552 | 0.018 | |
| VitC | 0.622 | 0.006 | |||||
| Lipid peroxides | −0.775 | 0.000 |
| MDA | −0.553 | 0.017 |
Regression analysis showing the relationships between five dependent variables and all other biomarkers. NE: norepinephrine, 5-HT: serotonin, DA: dopamine, GABA: gamma-aminobutyric acid, Glut: glutamate, Gln: glutamine, IFN-γ: interferon gamma, IFN-γ: interferon upsilon, IL-x: interleukin x, VEGF: vascular endothelial growth factor, TNF-α: tumor necrosis factor alpha, GSH: glutathione.
| Dependent Variable | Predictor Variable | Coefficient | S.E. | Adjusted R2 | 95% CI | Dependent Variable | Predictor Variable | Coefficient | S.E. | Adjusted R2 | 95% CI | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Lower | Upper | Lower | Upper | ||||||||||||
|
| Glut | 10.044 | 1.612 | 0.000 | 0.791 | 6.398 | 13.690 |
| IL-10 | 0.011 | 0.001 | 0.000 | 0.853 | 0.008 | 0.014 |
| Glut | 8.641 | 1.397 | 0.000 | 0.868 | 5.419 | 11.862 | IL-10 | 0.011 | 0.001 | 0.214 | 0.912 | 0.009 | 0.014 | ||
| IL-12 | −0.309 | 0.123 | 0.000 | −0.594 | −0.025 | IL-1A | 0.012 | 0.005 | 0.000 | 0.002 | 0.023 | ||||
| Glut | 6.986 | 0.712 | 0.000 | 0.972 | 5.303 | 8.668 | IL-10 | 0.011 | 0.001 | 0.000 | 0.946 | 0.009 | 0.013 | ||
| IL-12 | −0.408 | 0.060 | 0.000 | −0.549 | −0.266 | IL-1A | 0.012 | 0.004 | 0.014 | 0.003 | 0.020 | ||||
| Gln | 64.781 | 11.733 | 0.001 | 37.038 | 92.524 | IL-6 | −0.019 | 0.008 | 0.045 | −0.038 | 0.000 | ||||
| Glut | 3.695 | 1.219 | 0.023 | 0.987 | 0.712 | 6.678 |
| GABA | 1.205 | 0.158 | 0.000 | 0.851 | 0.848 | 1.563 | |
| IL-12 | −0.441 | 0.043 | 0.000 | −0.545 | −0.336 | GABA | 0.679 | 0.251 | 0.557 | 0.904 | 0.099 | 1.259 | |||
| Gln | 63.796 | 8.105 | 0.000 | 43.965 | 83.627 | DA | 0.138 | 0.057 | 0.027 | 0.007 | 0.269 | ||||
| IFN-ϒ | 0.143 | 0.049 | 0.026 | 0.024 | 0.262 |
| Glut | 22.035 | 2.923 | 0.000 | 0.848 | 15.423 | 28.646 | ||
| Glut | 2.785 | 0.897 | 0.027 | 0.994 | 0.479 | 5.092 |
| IL-12 | 2.832 | 1.228 | 0.047 | 0.301 | 0.053 | 5.611 | |
| IL-12 | −0.470 | 0.031 | 0.000 | −0.550 | −0.390 | IL-12 | 4.173 | 0.967 | 0.028 | 0.650 | 1.943 | 6.404 | |||
| Gln | 67.868 | 5.745 | 0.000 | 53.101 | 82.635 | Glut/Gln | 24.766 | 7.840 | 0.003 | 6.688 | 42.844 | ||||
| IFN-ϒ | 0.188 | 0.037 | 0.004 | 0.093 | 0.283 |
| VEGF | 80.798 | 10.535 | 0.000 | 0.853 | 56.965 | 104.631 | ||
| IL-10 | 0.004 | 0.002 | 0.039 | 0.000 | 0.008 | VEGF | 83.026 | 8.106 | 0.353 | 0.914 | 64.333 | 101.719 | |||
| Glut | 2.797 | 0.356 | 0.001 | 0.999 | 1.809 | 3.784 | IL-1A | −1.052 | 0.388 | 0.000 | −1.946 | −0.158 | |||
| IL-12 | −0.516 | 0.015 | 0.000 | −0.558 | −0.474 |
| TNF-α | −1.134 | 0.480 | 0.042 | 0.314 | −2.220 | −0.048 | ||
| Gln | 74.889 | 2.637 | 0.000 | 67.568 | 82.211 | TNF-α | −1.288 | 0.367 | 0.000 | 0.609 | −2.133 | −0.443 | |||
| IFN-ϒ | 0.221 | 0.016 | 0.000 | 0.176 | 0.265 | IFN-ϒ | −0.130 | 0.047 | 0.008 | −0.238 | −0.023 | ||||
| IL-10 | 0.005 | 0.001 | 0.001 | 0.003 | 0.007 |
| Glut/Gln | −3.272 | 0.864 | 0.004 | 0.571 | −5.227 | −1.317 | ||
| DA | 0.337 | 0.064 | 0.006 | 0.160 | 0.514 | Glut/Gln | −4.571 | 0.898 | 0.000 | 0.714 | −6.641 | −2.501 | |||
|
| Glut/Gln | 0.706 | 0.040 | 0.000 | 0.969 | 0.616 | 0.796 |
| GABA/Glut | 1.385 | 0.220 | 0.000 | 0.794 | 0.887 | 1.883 |
| Glut/Gln | 0.685 | 0.014 | 0.000 | 0.996 | 0.653 | 0.717 |
| NE | 3.149 | 0.436 | 0.000 | 0.836 | 2.162 | 4.136 | |
| Gln | 2.869 | 0.348 | 0.000 | 2.067 | 3.670 |
| GABA/Glut | 0.923 | 0.069 | 0.000 | 0.947 | 0.767 | 1.080 | ||
| Glut/Gln | 0.713 | 0.009 | 0.000 | 0.999 | 0.692 | 0.735 |
| TNF-α | 2.920 | 0.786 | 0.005 | 0.561 | 1.142 | 4.698 | |
| Gln | 2.581 | 0.188 | 0.000 | 2.137 | 3.025 |
| IL-12 | 0.207 | 0.056 | 0.005 | 0.561 | 0.081 | 0.334 | ||
| IFN-γ | 0.000 | 0.000 | 0.002 | 0.000 | 0.000 |
| Glut | 0.018 | 0.004 | 0.002 | 0.627 | 0.009 | 0.028 | ||
ROC-Curve of all variables in the PPA-treated and Bee pollen-protected groups. GABA: gamma-aminobutyric acid, Glut: glutamate, Gln: glutamine, IFN-γ: interferon gamma, IFN-γ: interferon upsilon, IL-x: interleukin x, VEGF: vascular endothelial growth factor, TNF-α: tumor necrosis factor alpha, GSH: glutathione.
| Parameters | Groups | AUC | Cut-off Value | Sensitivity | Specificity | 95% CI | |
|---|---|---|---|---|---|---|---|
|
| PPA-acute | 1 | 103.755 | 100.0% | 100.0% | 0.004 | 1.000–1.000 |
| Pollen | 0.694 | 82.67 | 100.0% | 50.0% | 0.262 | 0.369–1.020 | |
|
| PPA-acute | 1 | 3.955 | 100.0% | 100.0% | 0.004 | 1.000–1.000 |
| Pollen | 1 | 4.135 | 100.0% | 100.0% | 0.004 | 1.000–1.000 | |
|
| PPA-acute | 1 | 4.795 | 100.0% | 100.0% | 0.004 | 1.000–1.000 |
| Pollen | 1 | 5.105 | 100.0% | 100.0% | 0.004 | 1.000–1.000 | |
|
| PPA-acute | 1 | 16.52 | 100.0% | 100.0% | 0.004 | 1.000–1.000 |
| Pollen | 1 | 17.62 | 100.0% | 100.0% | 0.004 | 1.000–1.000 | |
|
| PPA-acute | 1 | 124.76 | 100.0% | 100.0% | 0.004 | 1.000–1.000 |
| Pollen | 1 | 119.845 | 100.0% | 100.0% | 0.004 | 1.000–1.000 | |
|
| PPA-acute | 1 | 2.275 | 100.0% | 100.0% | 0.004 | 1.000–1.000 |
| Pollen | 1 | 2.4 | 100.0% | 100.0% | 0.004 | 1.000–1.000 | |
|
| PPA-acute | 1 | 2.19 | 100.0% | 100.0% | 0.004 | 1.000–1.000 |
| Pollen | 1 | 1.67 | 100.0% | 100.0% | 0.004 | 1.000–1.000 | |
|
| PPA-acute | 1 | 1.29 | 100.0% | 100.0% | 0.004 | 1.000–1.000 |
| Pollen | 1 | 1.52 | 100.0% | 100.0% | 0.004 | 1.000–1.000 | |
|
| PPA-acute | 0.722 | 0.655 | 66.7% | 66.7% | 0.2 | 0.421–1.023 |
| Pollen | 0.569 | 0.665 | 83.3% | 50.0% | 0.689 | 0.221–0.918 | |
|
| PPA-acute | 1 | 3.295 | 100.0% | 100.0% | 0.004 | 1.000–1.000 |
| Pollen | 0.931 | 2.14 | 100.0% | 66.7% | 0.013 | 0.787–1.074 | |
|
| PPA-acute | 0.5 | 25.38 | 50.0% | 66.7% | 1 | 0.153–0.847 |
| Pollen | 0.833 | 8.445 | 75.0% | 100.0% | 0.088 | 0.524–1.143 | |
|
| PPA-acute | 0.633 | 207.35 | 50.0% | 80.0% | 0.465 | 0.288–0.979 |
| Pollen | 0.88 | 146.235 | 80.0% | 80.0% | 0.047 | 0.662–1.098 | |
|
| PPA-acute | 0.521 | 23.195 | 50.0% | 83.3% | 0.915 | 0.070–0.972 |
| Pollen | 0.6 | 16.88 | 60.0% | 83.3% | 0.584 | 0.205–0.995 | |
|
| PPA-acute | 0.812 | 122.27 | 100.0% | 75.0% | 0.149 | 0.465–1.160 |
| Pollen | 0.875 | 119.215 | 100.0% | 75.0% | 0.083 | 0.608–1.142 | |
|
| PPA-acute | 0.833 | 72.835 | 66.7% | 100.0% | 0.055 | 0.593–1.073 |
| Pollen | 0.861 | 72.13 | 83.3% | 100.0% | 0.037 | 0.604–1.119 | |
|
| PPA-acute | 0.597 | 4.5 | 66.7% | 66.7% | 0.575 | 0.253–0.941 |
| Pollen | 0.889 | 3.72 | 66.7% | 100.0% | 0.025 | 0.697–1.081 | |
|
| PPA-acute | 0.944 | 15.095 | 83.3% | 100.0% | 0.01 | 0.814–1.075 |
| Pollen | 0.833 | 14.845 | 83.3% | 100.0% | 0.055 | 0.535–1.132 | |
| Pollen | 0.861 | 54.89 | 100.0% | 66.7% | 0.037 | 0.645–1.077 | |
|
| PPA-acute | 0.667 | 37.41 | 83.3% | 50.0% | 0.337 | 0.346–0.987 |
| Pollen | 1 | 39.565 | 100.0% | 100.0% | 0.004 | 1.000–1.000 | |
|
| PPA-acute | 1 | 15.26 | 100.0% | 100.0% | 0.004 | 1.000–1.000 |
| Pollen | 0.583 | 20.485 | 66.7% | 66.7% | 0.631 | 0.234–0.933 | |
| Pollen | 0.639 | 0.355 | 66.7% | 66.7% | 0.423 | 0.301–0.977 |
Figure 2Average Bacterial counts in fecal samples of control, PPA-induced rodent model of autism, and bee pollen-protected autism model. NA: nutrient agar, MAC: MacConkey’s agar, BA: blood agar, CCFA: cycloserine cefoxitin fructose agar, BBE: Bacteroides bile esculin agar. Nutrient agar—Gram-positive/Gram-negative rods and cocci; MacConkey—Enterobacteriaceae (Gram-negative rods, lactose fermenters); Blood agar—Gram-positive/Gram-negative rods and cocci; CCFA (Cycloserine Cefoxitin Fructose Agar)—Clostridioides difficile; BBE (Bile Esculin Agar)—Bacteroidetes, streptococci, and enterococci.